Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume
Crossref DOI link: https://doi.org/10.1007/s12522-014-0198-9
Published Online: 2014-11-11
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Inoue, Tomoko
Hashimoto, Shu
Iwahata, Hideyuki
Ito, Keijiro
Nakaoka, Yoshiharu
Morimoto, Yoshiharu
Version of Record valid from 2014-11-11
Text and Data Mining valid from 2015-09-01